GlassScriptPhysician profile
Joseph Fred Stoner
NPI 1083614192
$1,801.66
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was more than what 82% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $92.89 · 2021: $171 · 2022: $362 · 2023: $88.35 · 2024: $528 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $248.84 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $222.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $163.93 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $130.41 | 2019-2023 | Xtampza |
| Vertical Pharmaceuticals, LLC | $124.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.99 | 2024 | |
| Braeburn INC. | $88.98 | 2025 | Brixadi |
| Alkermes, INC. | $86.57 | 2024 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $85.48 | 2019-2025 | Uzedy |
| Regeneron Healthcare Solutions, INC. | $85.14 | 2024 | Dupixent |
| Mylan Specialty L.P. | $84.50 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.83 | 2021 | |
| Impel Pharmaceuticals INC. | $57.17 | 2023 | Trudhesa |
| Sentynl Therapeutics, INC. | $52.44 | 2019 | |
| Daiichi Sankyo INC. | $35.59 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Appliedvr INC | $34.83 | 2024 | Relievrx |
| Virtus Pharmaceuticals LLC | $30.71 | 2021-2025 | Levorphanol Tartrate |
| Redhill Biopharma INC. | $18.45 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.23 | 2020 | |
| Pacira Therapeutics, INC. | $15.36 | 2019 | |
| Medline Industries LP | $15.10 | 2023 | Medline Industries, INC., Lidocaine Hydrochloride and Dextrose |
| Kaleo, INC. | $11.88 | 2019 | |
| Medtronic USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Stoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.